# Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer

> **NCT02467907** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 152 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02467907
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-28
- **Primary completion:** 2018-12-31
- **Final completion:** 2019-01-15
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2019-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02467907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02467907, "Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02467907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*